Which of the following is a primary action of entacapone when used with levodopa for clients with Parkinson's disease?

Parkinson’s disease is caused by decreased dopamine activity in the brain, leading to motor symptoms such as tremors, rigidity, and bradykinesia. Treatment commonly includes Entacapone in combination with levodopa to improve dopamine availability. Entacapone works by inhibiting the breakdown of levodopa in the periphery, allowing more of the drug to reach the brain. This enhances and prolongs the therapeutic effect of levodopa, improving motor control. Rationale: A. Inhibiting dopamine receptor activity in the CNS is incorrect because entacapone does not block dopamine receptors. Instead, it supports dopamine activity by increasing the amount of levodopa available for conversion into dopamine in the brain. Dopamine receptor blockade would actually worsen Parkinsonian symptoms. B. Decreasing the side effects of levodopa therapy is not the primary mechanism of entacapone. Although it may allow for lower doses of levodopa and indirectly reduce some side effects such as “wearing off,” its main action is pharmacokinetic enhancement of levodopa availability rather than direct side effect reduction. C. Enhancing the metabolism of levodopa in peripheral tissues is incorrect because entacapone actually inhibits, rather than enhances, levodopa metabolism. It blocks catechol-O-methyltransferase (COMT), an enzyme responsible for breaking down levodopa in the periphery. This increases the amount of levodopa that can cross the blood-brain barrier. D. Inhibiting the enzyme that breaks down levodopa is correct because entacapone selectively inhibits peripheral COMT. This prevents the conversion of levodopa into inactive metabolites before it reaches the central nervous system. As a result, more levodopa is available to be converted into dopamine in the brain, improving symptom control in Parkinson’s disease.